Senti Biosciences, Inc. 10-K — AI Bull & Bear Analysis

The 10-K reveals a company at a crossroads, where cutting-edge synthetic biology meets extreme financial fragility. The ability of Senti to survive depends entirely on the successful execution of its 'asset-light' strategy and the continued support of its manufacturing partner, GeneFab. While the RMAT designation provides a regulatory bridge, the gap between current liquidity and the cost of pivotal trials remains wide. Investors are essentially betting on a binary outcome: either SENTI-202 validates in expansion cohorts and triggers a massive re-rating through a strategic partnership, or the company succumb to its burn rate before reaching a liquidity event. The synthesis of the filing suggests that while the technology is validated at a signal level, the corporate structure remains high-risk and speculative.